<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651637</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1011-PR-0059</org_study_id>
    <nct_id>NCT01651637</nct_id>
  </id_info>
  <brief_title>First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome</brief_title>
  <official_title>A First in Human Clinical Study on the Safety and Tolerability of Two Escalating Single Doses of CHF 5633 (Synthetic Surfactant) in Preterm Neonates With Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the safety and tolerability of intratracheal&#xD;
      administration of two different single doses of CHF 5633 in preterm neonates with RDS in&#xD;
      terms of adverse events, adverse drug reactions, hematology and biochemistry values, the&#xD;
      incidence of major neonatal morbidities including bronchopulmonary dysplasia (BPD) and&#xD;
      mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a multicentre, open-label, single escalating dose, per-cohort design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 23, 2015</completion_date>
  <primary_completion_date type="Actual">January 23, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monitoring of adverse events following CHF5633 administration</measure>
    <time_frame>For duration of hospital stay (expected average of 9 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CHF 5633 efficacy profile (oxygenation , ventilatory requirements and need for rescue surfactant treatment),systemic absorption and immunogenicity assesment</measure>
    <time_frame>At min 30, at hrs 1, 3, 6, 12, 24, at days 2, 3, 7 and at days 10, 28, at 36 weeks pma post dosing for ventilatory requirements, at pre-dose and 3 hrs and 24 hrs post dosing for systemic absorption and at 8 wks after administration for immunogenicity</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Respiratory Distress Syndrome in Premature Infants</condition>
  <arm_group>
    <arm_group_label>Synthetic Surfactant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort Design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>synthetic surfactant (CHF5633)</intervention_name>
    <description>CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration</description>
    <arm_group_label>Synthetic Surfactant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained by parents/legal representative (according to local&#xD;
             regulation) prior to any study-related procedures&#xD;
&#xD;
          -  Inborn and outborn, preterm neonates of either sex with a gestational age of 27 weeks&#xD;
             up to 33 weeks+6&#xD;
&#xD;
          -  Clinical and radiological findings typical of RDS&#xD;
&#xD;
          -  Age on admission to the study &lt; 24 hours from birth&#xD;
&#xD;
          -  Requirement of endotracheal intubation for surfactant administration&#xD;
&#xD;
          -  Fraction of inspired oxygen (FiO2) &gt; 0.35 to maintain SpO2 between 90-95 %&#xD;
&#xD;
          -  Documentation of normal cranial ultrasound scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of surfactant prior to study entry and need for intratracheal administration of&#xD;
             any other treatment (e.g. nitric oxide)&#xD;
&#xD;
          -  Known genetic or chromosomal disorders, major congenital anomalies (cardiac&#xD;
             malformations, myelomeningocele etc)&#xD;
&#xD;
          -  Maternal drug abuse (heroin, methadone, methamphetamine, or cocaine) or significant&#xD;
             alcohol consumption during pregnancy&#xD;
&#xD;
          -  Clinical chorioamnionitis (Appendix III)&#xD;
&#xD;
          -  Strong suspicion of congenital pneumonia/infection, sepsis&#xD;
&#xD;
          -  Evidence of severe birth asphyxia or a 5 minutes Apgar score less / equal 3&#xD;
&#xD;
          -  Presence of air leaks prior to study entry&#xD;
&#xD;
          -  Neonatal seizures prior to study entry&#xD;
&#xD;
          -  Mothers with prolonged rupture of the membranes (&gt; 3 weeks duration)&#xD;
&#xD;
          -  Any condition that, in the opinion of the Investigator, would place the neonate at&#xD;
             undue risk&#xD;
&#xD;
          -  Participation in another clinical trial of any placebo, drug or biological substance&#xD;
             conducted under the provisions of a protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>27 Weeks</minimum_age>
    <maximum_age>34 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Speer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäts-Kinderklinik Würzburg (Germany)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Women's Hospital Neonatal Unit Liverpool Women's Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001331-22</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Sweet DG, Turner MA, Straňák Z, Plavka R, Clarke P, Stenson BJ, Singer D, Goelz R, Fabbri L, Varoli G, Piccinno A, Santoro D, Speer CP. A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 2017 Nov;102(6):F497-F503. doi: 10.1136/archdischild-2017-312722. Epub 2017 May 2.</citation>
    <PMID>28465315</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Distress syndrome</keyword>
  <keyword>Complications of prematurity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

